Tag: Cann Group Limited
Cann Group expects record revenue growth of 111% in FY23
Pharmaceutical company Cann Group Limited announced its FY23 unaudited results, with its operating revenue expected to be approximately $13.5 million, representing growth of 111 per cent or 2.1 times compared to the prior year revenue.
Cann granted GMP manufacturing licence for Mildura facility
The Therapeutic Goods Administration (TGA) has granted Cann Group Limited a GMP licence to manufacture therapeutic goods, which includes GMP testing at its Mildura facility.
Cann...
Cann Group supplies medicinal cannabis for Australian clinical trial for advanced cancer patients
Cann Group Limited is supplying medicinal cannabis for Australian clinical trial assessing quality of life impacts for advanced cancer patients.
The trial, which is being...
Featured Article
What spending reveals about downstream consumer demand for manufactured goods
For manufacturers supplying consumer-facing markets, understanding demand conditions has become increasingly important in an environment shaped by cautious spending, rising costs and intense competition.
